Ishih Akira, Suzuki Tohru, Muregi Francis W, Matsui Kae, Terada Mamoru
Department of Parasitology, Hamamatsu University School of Medicine, Japan.
Southeast Asian J Trop Med Public Health. 2006 Jan;37(1):13-7.
We examined whether the initial number of parasites inoculated and the starting day of medication post-infection influenced the antimalarial efficacy of chloroquine (CQ) against Plasmodium berghei NK65 infection in ICR mice. Male ICR mice were inoculated intraperitoneally with 1 x 10(5), 1x10(6), 1 x 10(7), 1 x 10(8) P. berghei NK65-parasitized erythrocytes (pRBC). In the treated group, all mice received an oral dose of 20 mg/kg of CQ base for 4 days starting on day 0 after infection. From day 3, Giemsa-stained thin blood smears from tail vein blood were used to assess parasitemia. Mice in the untreated control in each group showed a progressive increase in parasitemia leading to death. Treatment of mice, inoculated with 1 x 10(5), 1 x 10(6) and 1 x 10(7) pRBC, with CQ showed a marked effect. All the mice survived during the experiment. During the observation period, malaria parasites could not be detected on microscopic examination. Conversely, mice inoculated with 1 x 10(8) pRBC showed little response to CQ treatment, and all mice showed a progressive increase in parasitemia and ultimately died. In another experiment, mice infected with 1 x 10(3) and 1x 10(5) pRBC were treated with an oral four-day dosage of 20 mg/kg of CQ base from days 2, 3 or 4 post-infection. Treatment of mice, inoculated with 1 x 10(3) pRBC, with CQ from days 2 and 3 showed a marked effect. All mice survived during the experiment. However, treatment from day 4 showed a limited derease in parasitemia and all the mice ultimately died. On the other hand, treatment from day 2 showed a marked effect against 1 x 10(5) P. berghei NK65-infected mice, but treatment from days 3 or 4 was only slightly effective and all the mice died with an increasing parasitemia. The present results indicate that in in vivo antimalarial drug-assay systems, several factors, sush as initial parasite load and starting time of treatment may influence the drug response in the host.
我们研究了接种的寄生虫初始数量以及感染后开始用药的时间是否会影响氯喹(CQ)对ICR小鼠伯氏疟原虫NK65感染的抗疟效果。雄性ICR小鼠腹腔注射接种1×10⁵、1×10⁶、1×10⁷、1×10⁸个感染伯氏疟原虫NK65的红细胞(pRBC)。在治疗组中,所有小鼠在感染后第0天开始口服20mg/kg的CQ碱,持续4天。从第3天起,用吉姆萨染色的尾静脉血薄血涂片评估疟原虫血症。每组未治疗的对照小鼠疟原虫血症逐渐增加,最终导致死亡。用CQ治疗接种1×10⁵、1×10⁶和1×10⁷个pRBC的小鼠显示出显著效果。所有小鼠在实验期间存活。在观察期内,显微镜检查未检测到疟原虫。相反,接种1×10⁸个pRBC的小鼠对CQ治疗反应很小,所有小鼠疟原虫血症逐渐增加,最终死亡。在另一项实验中,感染1×10³和1×10⁵个pRBC且在感染后第2、3或4天接受口服4天剂量20mg/kg CQ碱治疗的小鼠。从第2天和第3天用CQ治疗接种1×10³个pRBC的小鼠显示出显著效果。所有小鼠在实验期间存活。然而,从第4天开始治疗,疟原虫血症仅有有限下降,所有小鼠最终死亡。另一方面,从第2天开始治疗对感染1×10⁵个伯氏疟原虫NK65的小鼠显示出显著效果,但从第3天或第4天开始治疗效果甚微,所有小鼠均因疟原虫血症增加而死亡。目前的结果表明,在体内抗疟药物检测系统中,诸如初始寄生虫负荷和治疗开始时间等几个因素可能会影响宿主对药物的反应。